Acelyrin - SLRN STOCK NEWS

ACELYRIN (SLRN) has implemented a -duration stockholder rights plan in response to Tang Capital Partners' rapid accumulation of 8.8% of outstanding common stock. The plan, effective immediately until March 12, 2026, issues one right per common stock share as of March 24, 2025.

Under the Rights Plan, if any person acquires 10% or more of the company's outstanding common stock (20% for Schedule 13G reporters), rights holders can purchase additional shares at the exercise price, with a market value of twice that price. Current stockholders exceeding these thresholds can maintain their positions but cannot acquire additional shares without triggering the plan.

The plan includes flip-over and exchange features, with Guggenheim Securities serving as financial advisor and Fenwick & West LLP and Paul Hastings LLP as legal counsel.

ACELYRIN (SLRN) and Alumis have reaffirmed their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases. The merger is expected to close in Q2 2025.

The combined entity will have a pro forma cash position of approximately $737 million as of December 31, 2024, providing runway into 2027. This includes Alumis's $289 million and ACELYRIN's $448 million in cash, cash equivalents, and marketable securities.

The merged company will focus on developing a late-stage portfolio including ESK-001 for psoriasis and lupus, lonigutamab for thyroid eye disease, and A-005 for multiple sclerosis. The transaction requires stockholder approval from both companies and satisfaction of customary closing conditions.

ACELYRIN (SLRN) has rejected an unsolicited indication of interest from Concentra Biosciences, controlled by Tang Capital Partners, in favor of proceeding with its planned merger with Alumis Inc. (ALMS). The company's Board of Directors, after consulting with independent financial and legal advisors, determined that Concentra's proposal would not result in a superior outcome compared to the existing all-stock transaction with Alumis.

The merger with Alumis is expected to close in Q2 2025, subject to stockholder approval from both companies and other customary closing conditions. ACELYRIN's Board maintains that the Alumis merger maximizes long-term value for stockholders and continues to recommend their support. Guggenheim Securities serves as financial advisor, while Fenwick & West and Paul Hastings provide legal counsel.

ACELYRIN (Nasdaq: SLRN) has received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The offer includes $3.00 per share in cash plus a contingent value right representing 80% of net proceeds from any out-license or disposition of ACELYRIN's development programs or intellectual property.

This offer comes after ACELYRIN's February 6, 2025 announcement of a planned all-stock merger with Alumis Inc. (Nasdaq: ALMS), which is expected to close in Q2 2025, subject to stockholder approvals and customary conditions. The ACELYRIN Board is evaluating the offer while maintaining its commitment to stockholder interests and existing merger agreement obligations.

Alumis and ACELYRIN have announced a merger agreement to create a late-stage clinical biopharma company focused on immune-mediated diseases. The all-stock transaction will result in Alumis stockholders owning ~55% and ACELYRIN stockholders ~45% of the combined company.

The merged entity will operate under the Alumis name with a pro forma cash position of approximately $737 million as of December 31, 2024, providing runway into 2027. Key pipeline assets include ESK-001, currently in Phase 3 trials for psoriasis with topline data expected in H1 2026, and lonigutamab for thyroid eye disease.

The transaction is expected to close in Q2 2025, subject to stockholder approval. The combined company will be led by the current Alumis executive team and headquartered in South San Francisco.

ACELYRIN (SLRN) has announced additional Phase 2 data and Phase 3 program design for lonigutamab in Thyroid Eye Disease (TED). The Phase 2 trial demonstrated clinically meaningful improvements across TED manifestations, including proptosis, Clinical Activity Score, and diplopia. The drug showed significant response rates with a 50 mg loading and 25 mg weekly subcutaneous dose.

The Phase 3 LONGITUDE program will include two global trials across ~350 patients, evaluating a 100 mg loading dose followed by 50 mg every two weeks. The trials will begin in Q1 2025, with topline data expected in second half of 2026. LONGITUDE-1 and 2 will study both 'active' and 'chronic' TED patients, with primary endpoints measuring proptosis response rate at 24 weeks.

The company received FDA alignment on the Phase 3 trial designs in Q3 2024 and maintains a cash runway through mid-2027.

ACELYRIN (Nasdaq: SLRN) announced a virtual investor event scheduled for January 6, 2025, at 4:30 PM ET. The event will present updated Phase 2 data for subcutaneous lonigutamab in Thyroid Eye Disease (TED) treatment, highlighting its potential for best-in-class efficacy and safety profile.

The company will also unveil the design of their Phase 3 LONGITUDE program, developed after a successful End-of-Phase 2 FDA meeting, which aims to be the most inclusive registrational program in TED to date. The presentation will feature external clinical perspectives from Stanford and University of Colorado School of Medicine experts on TED's unmet needs.

ACELYRIN (Nasdaq: SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis failed to meet its primary endpoint of showing statistically significant improvement in time to treatment failure versus placebo at 24 weeks. Secondary endpoints also did not achieve statistical significance.

Following these results and previous guidance, ACELYRIN will discontinue internal investment in izokibep development. The company will focus on advancing lonigutamab for thyroid eye disease (TED), with Phase 3 trials scheduled to begin in Q1 2025. The company reports $562.4 million in cash and equivalents as of September 30, 2024, providing runway until mid-2027.

ACELYRIN (NASDAQ: SLRN) reported Q3 2024 financial results with key updates on its pipeline. The company expects topline data from izokibep's Phase 2b/3 trial for uveitis treatment in December 2024. Following positive FDA interaction, lonigutamab's Phase 3 development for thyroid eye disease will begin in Q1 2025. Financial highlights include cash position of $562.4 million expected to fund operations until mid-2027, R&D expenses of $31.6 million (down from $74.6 million in Q3 2023), and net loss of $48.5 million (improved from $83.9 million in Q3 2023). The quarter included $10.8 million in restructuring expenses related to pipeline refocusing.